In this context, particularly interesting was the study carried out by Santiago-Walker and coworkers and based on the analysis of the use of ctDNA analysis in four clinical studies involving the treatment of BRAF-mutated melanomas with BRAF/MEK inhibitors [283]. Here, MAP2K7 is linked to melanoma.